Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It was actually was selling higher and of course
NITE playing games with it. still happy though.
re: EAGB,
I seen an S-8 out 07/05/07
however, thought this sched. 13d filed this morn was interesting
Percent of Class Represented by Amount in Row (11)
Approximately 13.27%
Charlton Conine
Shares Purchased for the Reporting Person:
Person Quantity Date Unit Cost Where & How Transacted
Charlton Conine 10,000 2/09/07 0.43 Buy, Morgan Stanley Account
Charlton Conine 90,000 3/29/07 0.21 Buy, Morgan Stanley Account
Charlton Conine 100,000 4/03/07 0.22 Buy, Morgan Stanley Account
Charlton Conine 22,000 4/03/07 0.23 Buy, Morgan Stanley Account
Charlton Conine 100,000 4/05/07 0.19 Buy, Morgan Stanley Account
Charlton Conine 20,000 4/11/07 0.17 Buy, Morgan Stanley Account
Charlton Conine 80,000 4/11/07 0.17 Buy, Morgan Stanley Account
Charlton Conine 100,000 4/16/07 0.16 Buy, Morgan Stanley Account
Charlton Conine 100,000 4/18/07 0.16 Buy, Morgan Stanley Account
Charlton Conine 25,000 4/26/07 0.17 Buy, Morgan Stanley Account
Charlton Conine 10,000 4/30/07 0.18 Buy, Morgan Stanley Account
Charlton Conine 26,000 4/30/07 0.19 Buy, Morgan Stanley Account
Charlton Conine 200,000 5/01/07 0.20 Buy, Morgan Stanley Account
Charlton Conine 37,000 5/02/07 0.21 Buy, Morgan Stanley Account
Charlton Conine 21,000 5/02/07 0.19 Buy, Morgan Stanley Account
Charlton Conine 30,500 5/08/07 0.21 Buy, Morgan Stanley Account
Charlton Conine 100,000 5/16/07 0.18 Buy, Morgan Stanley Account
Charlton Conine 100,000 5/18/07 0.18 Buy, Morgan Stanley Account
Charlton Conine 100,000 5/22/07 0.17 Buy, Morgan Stanley Account
Charlton Conine 125,700 6/06/07 0.17 Buy, Morgan Stanley Account
Charlton Conine 80,000 6/14/07 0.16 Buy, Morgan Stanley Account
Charlton Conine 150,000 6/19/07 0.15 Buy, Morgan Stanley Account
Charlton Conine 75,000 6/26/07 0.11 Buy, Morgan Stanley Account
Charlton Conine 300,000 7/03/07 0.09 Buy, Morgan Stanley Account
Charlton Conine 520,000 7/05/07 0.10 Buy, Morgan Stanley Account
Charlton Conine 500,000 7/05/07 0.10 Buy, Morgan Stanley Account
Charlton Conine 500,000 7/06/07 0.09 Buy, Morgan Stanley Account
Charlton Conine 500,000 7/09/07 0.09 Buy, Morgan Stanley Account
Charlton Conine 500,000 7/11/07 0.09 Buy, Morgan Stanley Account
Out my CTUV post f/s (CVNE) for more then double, watching this one for the merger that was PR'd. been some nice buying up to 2.20 recently.
fwiw
CYRR 10 avg volume 5500 today 126k so far, like this one and watching fwiw.
"the same old crew seems to dump this stock", yes thats why we were hoping for a change...!
ps: U R not fooling anyone.
Yes I noticed that, sell 100k buy 10k...sad
lol...and I am still shaking my head.
Whats with all the new aliases born lately?
I disagree, I have seen you eat...lol
AFSE - ALL Fuels & Energy Receives Letter of Intent for $121 Million in Funding for Strategic Acquisitions
Jul 12, 2007 11:19:00 AM
JOHNSTON, IA -- (MARKETWIRE) -- 07/12/07 -- ALL Fuels & Energy Company (PINKSHEETS: AFSE), today announced that it has received a letter of intent to provide $121 million of funding. Funds will be used by AFSE for strategic acquisitions of operational ethanol plants.
"After evaluating several potential funding sources with knowledge of ALL Fuels & Energy management and growth model, we have identified superior debt and equity groups with which to partner. We look forward to working with these quality financing partners as we complete our acquisitions," said Dean Sukowatey, AFSE's President.
About ALL Fuels & Energy Company
Visit the company online at: www.allenergycompany.com.
ALL Fuels & Energy Company (AFSE) recently acquired ALL Energy Company, a development-stage ethanol company organized to operate as an ethanol producer, focusing primarily on the production and sale of ethanol and its co-products. AFSE has adopted the business plan of ALL Energy Company. To date, AFSE has: obtained $2 million in private equity funding; purchased 150 acres on which to build its proposed ethanol production facility in Manchester, Iowa; signed a five-plant engineering and design agreement with Delta-T Corporation (Delta-T is a Virginia-based company with over twenty years of experience in the ethanol industry that management believes possesses superior expertise and superior technologies in the ethanol production space); engaged Natural Resources Group to handle water-related environmental matters relating to the proposed Manchester ethanol production facility; through the efforts of its air-related environmental consultant, Yaggy-Colby, obtained the final Air Quality Construction Permit, relating to the proposed Manchester ethanol production facility; and investigated and become involved in the potential acquisition of one or more existing ethanol production facilities, including Ace Ethanol.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe AFSE's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the ability of AFSE to obtain needed financing, as well as the financial performance of AFSE, which could cause actual results to differ materially from those anticipated. Although AFSE believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it cannot give any assurance that such expectations will be fulfilled. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release, and AFSE does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
ALL Fuels & Energy Company
Dean Sukowatey
President
515-331-6509
allenergycompany@gmail.com
HSBC Launches International Survey of Public Attitudes towards Climate Change
New Research Shows Developing Countries Most Concerned About Need to Combat Climate Change
Jul 12, 2007 11:00:00 AM
Copyright Business Wire 2007
NEW YORK--(BUSINESS WIRE)--
HSBC's first international survey of public attitudes towards climate change highlights a surprising spectrum of opinions across the world. Climate change may be a global issue, but reactions to it vary strongly. The HSBC Climate Confidence Index shows that people in developing economies exhibit the greatest concern, commitment and optimism towards the problem of climate change and in developed economies the greatest indifference, reluctance and fatalism.
Overall, the survey reveals that citizens of China and India are most optimistic that the problem of climate change can be overcome, while those in France, Germany and the UK are least optimistic that a solution will be found with the US, Mexico, Brazil and Hong Kong falling somewhere in between..
The research, based on a sample of 9,000 people in nine countries and territories, across four continents, also demonstrates that:
-- Climate change is having a significant impact on public
opinion in the developing countries surveyed. Around 60
percent of respondents registered a high level of concern in
China, India, Mexico and Brazil. In the U.S., 32 percent of
Americans are concerned with climate change compared with only
22 percent in the UK and 26 percent in Germany. Climate change
is the 4th major concern among Americans behind terrorism,
healthcare and planning for retirement.
-- People's assessment of their commitment to tackling climate is
higher in developing economies. Around 47 percent of people
indicated high levels of personal commitment to combating
climate change in India and Brazil, compared with only 19
percent in the UK.
"The HSBC Climate Confidence Index is an important barometer of international public attitudes towards climate change," said John Beckinghausen, Director, Sustainable Development & Operations, Corporate Real Estate, HSBC Bank USA, N.A. "Over time we believe it will enable us to better understand the actions individuals are prepared to take in reducing their carbon footprint and how we can work with governments and the business community to provide financial solutions to support them."
The index also highlights the emergence of so-called 'green rejection' in the developed world - a rejection that climate change is a problem, of solutions to it and of the institutions proposing them. Green rejection is strongest in the UK and Germany, where respondents were among the least engaged and optimistic about the challenge. In the US, respondents were by far the most confident and optimistic of all the developed economies surveyed. In fact, 18 percent of Americans responded that they believe we will stop climate change and 32 percent agreed that the people and organizations who should be doing something about climate change were taking action.
With regard to whose responsibility it is to tackle the problem, a clear majority of all respondents across countries and age groups - 68 percent - believe that governments should be playing the leading role, compared with NGOs, companies and individuals. However, only 33 percent felt that governments play this role today.
The launch of the HSBC Climate Confidence Index is part of HSBC's broader strategy to contribute to tackling climate change. Other initiatives include the Global Environmental Efficiency Programme, a US$90m commitment to reduce its own direct environmental impacts; the Carbon Finance Strategy, to help clients respond to the challenges and opportunities of creating a low-carbon economy; and the HSBC Climate Partnership, a US$100m program involving four of the world's most respected environmental groups and HSBC's 315,000 employees in helping reduce the impacts of climate change worldwide.
HSBC has also recently announced the appointment of Sir Nicholas Stern as its Special Adviser on Economic Development and Climate Change.
For a complete copy of the HSBC Climate Confidence Index or specific US-data please contact: Francine Minadeo at 212-525-8737 or francine.v.minadeo@us.hsbc.com
Note to editors
HSBC Climate Confidence Index
In one of the biggest research projects of its kind ever undertaken, nine thousand respondents completed an internet based survey in nine countries and their answers were analysed and converted into an index indicating the level of concern. The countries surveyed were: Brazil, China, France, Germany, Hong Kong SAR, India, Mexico, UK and USA. For further information, please go to: www.hsbc.com
HSBC Holdings plc - www.hsbc.com
The HSBC Group is one of the largest banking and financial services organisations in the world. The Group has around 10,000 offices in 82 countries and territories in Europe, the Asia-Pacific region, the Americas, the Middle East and Africa, serves over 125 million customers and has assets of US$1,861 billion as 31 December 2006. HSBC was the first major bank - and the first FTSE 100 company - to become carbon neutral.
Source: HSBC Holdings plc
----------------------------------------------
HSBC Holdings
Francine Minadeo
212-525-8737
francine.v.minadeo@us.hsbc.com
GLDS - Air Industries Announces $4.1 Million Order From Goodrich Division for Airbus A380 Landing Gear Parts
Jul 12, 2007 10:43:00 AM
Copyright Business Wire 2007
BAY SHORE, N.Y.--(BUSINESS WIRE)--
Air Industries Group, Inc. (OTCBB: GLDS) (formerly Gales Industries), a holding company established to consolidate manufacturers, engineering integrators and specialized service providers to the aerospace/defense industry, today announced that its wholly-owned operating subsidiary, Air Industries Machining Corp. (AIM), received orders totaling $4.1 million from Goodrich Aerospace Canada Ltd, a Landing Gear division of Goodrich Corporation (NYSE: GR). The orders are for Landing Gear Drag Strut Assemblies on the Airbus A380 aircraft. These orders are incremental contractual releases against a long term agreement announced earlier in the year.
"Today's announcement highlights continued important and sizeable awards for AIM as a supplier of critical aircraft parts," said Peter Rettaliata, Chief Executive Officer of Air Industries Group. "Our recent contract awards reflect our strengthened position within the supply chain supporting the world's leading commercial aircraft builders. Furthermore, we have markedly progressed in our overarching business pursuits of internally generated revenue growth and diversification for our manufacturing platform."
The A380 is a double-deck, four-engine airliner manufactured by Airbus Corporation, a division of European Aeronautic Defence and Space Company EADS N.V. (EADS). Hailed as Airbus' 21st century flagship, the A380 Aircraft Family introduces a new era of airline transportation, carrying 525 passengers aboard the most advanced, spacious and efficient aircraft ever conceived, according to the company. Designed as the largest passenger airliner in the world, the A380 has been modified as a freighter plane for commercial cargo shipments. The jetliner has a maximum takeoff weight of 590 metric tons (1,300,000 lbs.) and a range of 15,200 km/8,200 nm. The A380's maiden flight was on April 27, 2005 from Toulouse, France. Since its introduction, a total of 165 A380 airplanes have been ordered to date.
Goodrich Corporation, a Fortune 500 company, is a global supplier of systems and services to the aerospace, defense and homeland security markets. With annual revenues of $5.9 billion, Goodrich is headquartered in Charlotte, North Carolina, and employs more than 23,000 people worldwide in over 90 facilities across 16 countries.
Goodrich Landing Gear is the leading producer of aerospace landing gear components, assemblies and associated hydraulic systems. Its production of world class landing systems is based largely on a network of approved purchased product suppliers, including Air Industries Machining Corp., located throughout the world. These suppliers have been selected and approved based on their ability to meet Goodrich Landing Gear's highest standards in supplier quality systems and product. The Landing Gear Division supports commercial, military, regional and business customers throughout the world. Customers include Boeing Commercial and Military, Lockheed-Martin, Airbus, Bombardier, Gulfstream, Agusta, Sikorsky and the United States government.
ABOUT AIR INDUSTRIES GROUP, INC.
Air Industries Group, Inc. (OTCBB: GLDS) (formerly Gales Industries) is a holding company established to consolidate manufacturers, engineering integrators and specialized service providers to the aerospace/defense and commercial aviation industries. The Company is focused on flight safety and other critical componentry. Consolidation opportunities include companies operating within highly synergistic disciplines of manufacturing, technical services and strategic products distribution. The Company's strategy is to execute its consolidation principally amongst middle market aerospace/defense subcontractors. Air Industries Group offers a tailored exit strategy or management continuity strategy in exchange for qualified acquisitions, and targets technically superior organizations with revenues of up to $100 million annually. Information on the Company and its products may be found online at www.airindmc.com.
Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, firm backlog, projected backlog, potential future results and acquisitions, are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates, projections and forecasts made by management with respect to the Company's critical accounting policies, firm backlog, projected backlog, regulatory delays, government funding and budgets, matters pertaining to potential and pending acquisitions subject to and after closings, and other factors, including results of financial audits and general economic conditions, not within the Company's control. Certain of the Company's forward looking statements, with the projected backlog in particular, are formulated based on management's extensive industry experience and understanding and assessment of industry trends, customer requirements, and related government spending. Projected backlog may be subject to variability and may increase or decrease at any time based on a variety of factors, including but not limited to modifications of previously released orders, acceleration of orders under general purchase agreements, etc. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Source: Air Industries Group, Inc.
----------------------------------------------
Darrow Associates
Inc.
Jordan M. Darrow
631-367-1866
jdarrow@darrowir.com
Shaking my head.
RCAU - RocketCity (RCAU) Board Of Directors Announce Two-For-One Stock Split.
Jul 11, 2007 3:46:00 PM
Copyright Business Wire 2007
ORLANDO, Fla.--(BUSINESS WIRE)--
Rocket City Automotive Group, Inc. (Pink Sheets:RCAU), announced today that its Board of Directors has authorized a payment of a common stock dividend. All shareholders on record as of August 1, 2007 will be issued one (1) additional share of common stock for every common share held.
Subject to the approval of an effective date by the NASDAQ, the aforementioned stock dividend will be paid and become effective on August 3, 2007. The payment of the dividend will not require an increase in the total number of authorized shares of common stock nor is there a need for an exchange of certificates. RCAU will retain its current trading symbol and continue on course with intended business.
"The Rocket City organization continues to grow at a tremendous rate. As we presently occupy a position of strength within the industry and in the public marketplace, we have elected to implement the described stock split to increase investor interest as well as improve stock liquidity. We are excited about the progress of the overall organization and feel that we have only seen the beginning to what we believe to be a successful and rewarding future for both RCAU and its supporting shareholders," stated Jeff Roman, CEO of Rocket City Automotive Group.
About Rocket City Automotive Group, Inc.:
CompleteAuto, a subsidiary of Rocket City Automotive Group, Inc. (Pink Sheets: RCAU) offers proprietary software, personnel and design solutions to hundreds of automotive dealerships around the country. CompleteAuto is a wholly owned subsidiary of RocketCity which was formed to acquire, manage supervise and operate corporations specializing in auction services, eCommerce, software development and retail automotive operations.
CompleteAuto and RocketCity believe there are enormous growth opportunities in the $1 trillion automotive retailing industry. The experienced management team will continue to execute strategic initiatives to maximize operations in this marketplace with their products and services. Visit them on the web at www.RCAU.com to learn more.
Learn more about Complete Auto by visiting: www.completeauto.com
Disclaimer:
Cautionary Statement about Forward-Looking Statements
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook.
Source: Rocket City Automotive Group, Inc.
----------------------------------------------
Rocket City Automotive Group/CompleteAuto
Orlando
Investor Relations:
Ian Feller
Vice President of Corporate Communications
407-219-3770
invest@RCAU.com
CWLXF - Diamond Drilling Program Has Now Commenced on the Curlew Lake Typhoon Gold Property. Curlew Lake Holds a 100% Interest in the 23 Square Kilometer Property
Jul 12, 2007 9:10:00 AM
LANGLEY, BRITISH COLUMBIA -- (MARKETWIRE) -- 07/12/07 -- Curlew Lake Resources Inc. (TSX VENTURE: CWQ)(PINK SHEETS: CWLXF) reports good progress on its summer exploration program on the Typhoon Gold Property in the Yukon. The start of the 2007 exploration program was announced in a News Release dated 4 June 2007. A tent camp was set up on the claim block and exploration work carried out to date includes line cutting, an IP survey, additional magnetometer and geochemical surveys, and geological mapping. A Diamond Drilling program has now commenced to test some of the prospective anomalies identified by surface exploration programs completed in this and prior years. Curlew Lake is running a QA/QC program consistent with National Instrument 43-101 and industry best practices.
Curlew Lake holds a 100% interest in 117 mineral claims on the project, covering an area of approximately 23 square kilometers (about 9 square miles). The property is well situated for mineral exploration as it is accessible by a good gravel road connecting to the Klondike Highway about 100 kms southeast of Dawson City, Yukon.
The program is being managed by Aurora Geosciences Ltd. of Whitehorse, Yukon, under the supervision of Mike Wark, P. Geol. Jim Turner, P. Geol., a "Qualified Person" under National Instrument 43-101, is overseeing the program on behalf of the Company.
Significant results will be reported in a timely manner.
For additional information or to be added to the corporate mailing list please visit the following page http://www.curlew-lake.com/cwq/mail.html
On Behalf of the Board of Directors
Robert B. Pincombe, President
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Contacts:
Curlew Lake Resources Inc.
David D. McKee
Chief Financial Officer
(647) 722-3454
(647) 722-4337 (FAX)
Email: david.mckee@curlew-lake.com
Website: www.curlew-lake.com
Hate to have to feed that thing...lol
RCAU - RocketCity (RCAU) Board Of Directors Announce Two-For-One Stock Split.
Jul 11, 2007 3:46:00 PM
Copyright Business Wire 2007
ORLANDO, Fla.--(BUSINESS WIRE)--
Rocket City Automotive Group, Inc. (Pink Sheets:RCAU), announced today that its Board of Directors has authorized a payment of a common stock dividend. All shareholders on record as of August 1, 2007 will be issued one (1) additional share of common stock for every common share held.
Subject to the approval of an effective date by the NASDAQ, the aforementioned stock dividend will be paid and become effective on August 3, 2007. The payment of the dividend will not require an increase in the total number of authorized shares of common stock nor is there a need for an exchange of certificates. RCAU will retain its current trading symbol and continue on course with intended business.
"The Rocket City organization continues to grow at a tremendous rate. As we presently occupy a position of strength within the industry and in the public marketplace, we have elected to implement the described stock split to increase investor interest as well as improve stock liquidity. We are excited about the progress of the overall organization and feel that we have only seen the beginning to what we believe to be a successful and rewarding future for both RCAU and its supporting shareholders," stated Jeff Roman, CEO of Rocket City Automotive Group.
About Rocket City Automotive Group, Inc.:
CompleteAuto, a subsidiary of Rocket City Automotive Group, Inc. (Pink Sheets: RCAU) offers proprietary software, personnel and design solutions to hundreds of automotive dealerships around the country. CompleteAuto is a wholly owned subsidiary of RocketCity which was formed to acquire, manage supervise and operate corporations specializing in auction services, eCommerce, software development and retail automotive operations.
CompleteAuto and RocketCity believe there are enormous growth opportunities in the $1 trillion automotive retailing industry. The experienced management team will continue to execute strategic initiatives to maximize operations in this marketplace with their products and services. Visit them on the web at www.RCAU.com to learn more.
Learn more about Complete Auto by visiting: www.completeauto.com
Disclaimer:
Cautionary Statement about Forward-Looking Statements
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook.
Source: Rocket City Automotive Group, Inc.
----------------------------------------------
Rocket City Automotive Group/CompleteAuto
Orlando
Investor Relations:
Ian Feller
Vice President of Corporate Communications
407-219-3770
invest@RCAU.com
Just verified float, still the same 3 million. and btw
thnx for the .30 shares
SBEI - Neonode Adds a Substantial Deal to Its Expanding Order Book, This Time From Telenor
Jul 11, 2007 1:32:00 PM
Copyright Business Wire 2007
STOCKHOLM, Sweden--(BUSINESS WIRE)--
Neonode, the Swedish developer of mobile devices and pioneer in buttonless, touch screen mobile phones, has received a considerable order from the operator, Telenor Sweden, for the new Neonode N2.
Neonode announced today that it has received a considerable order from the operator, Telenor Sweden, a leading provider of complete communication services such as mobile and fixed telephone and data services. With the order, Neonode N2 will be distributed starting in September 2007 through Telenor Sweden's own stores, partner stores as well as Telenor Xpress, the company's sales event organization.
"We are happy to present another innovative Scandinavian brand in our portfolio. Neonode is one of the companies that are capable of presenting the next big thing on the market and also leading the way," said Anders Jensen, Marketing Director of Telenor Sweden.
Neonode was previously this year named to the annual FierceWireless "Fierce 15" list, designating it as one of the top wireless companies of the year. The company recently launched Neonode N2 in south-eastern Europe as its inaugural region.
"We are delighted to add another well respected partner to our list of customers. Telenor with its strong market presence and consumer acceptance is the perfect partner for Neonode's home market," said Mikael Hagman, President and CEO of Neonode.
Neonode is currently finalizing additional agreements with several partners in Europe and other major markets. The company is also merging with SBE, Inc., a publicly-traded company (NASDAQ:SBEI) pending SBE shareholder approval on August 10, 2007.
About Neonode
Neonode was founded in 2001 and is a Swedish developer of mobile devices. The mobile devices are based on patented technologies which enable a unique user experience. Neonode Inc. has recently announced the execution of a definitive merger agreement with SBE, Inc., a publicly-traded company (NASDAQ:SBEI). After shareholder approval of the merger, the combined company's headquarters will be in Stockholm, Sweden, where Neonode's current corporate headquarters is located. For more information visit www.neonode.com.
Source: Neonode
----------------------------------------------
Neonode
Mikael Hagman
President and CEO
+46 8 678 18 50
Daniel Stalbo
Marketing Director
+46 8 678 18 50
www.neonode.com
www.telenor.se
GLDS - Air Industries Announces Firm $48 Million Backlog - The Largest in Company History
Jul 11, 2007 10:15:00 AM
Copyright Business Wire 2007
BAY SHORE, N.Y.--(BUSINESS WIRE)--
Air Industries Group, Inc. (OTCBB: GLDS) (formerly Gales Industries) today announced a firm 18-month backlog that was in excess of $48.0 million as of June 30, 2007. This backlog level, which is solely derived from business relating to Air Industry Group's wholly-owned operating subsidiary, Air Industries Machining Corp. (AIM), is the largest in the Company's history. The backlog at June 30th reflects a 29% increase as compared to the prior firm backlog of $37.3 million as of March 31, 2007.
"AIM has capitalized on the internal growth initiatives put into place last year," said Peter Rettaliata, Chief Executive Officer of Air Industries Group. "This progress reflects a diversification of awards from both new and existing customers, for new and follow-on product orders, and from both commercial and defense programs. While our diversification strategy is being implemented throughout the Company, the record backlog reported today is only for one of our operating subsidiaries and does not include contributions from our other acquisition. On a consolidated basis, our current position and future outlook are far stronger than our published backlog and past operating performance indicate. We believe the favorable industry environment and our expanded business platform portend significant future growth for Air Industries Group, something which we are now demonstrating."
The firm backlog at June 30, 2007, represents fully authorized orders for products to be delivered within the next 18 months. Additionally, Air Industry Group's projected backlog, which includes both the firm backlog as well as anticipated order releases, totaled approximately $65 million at June 30, 2007. These figures do not include orders relating to Sigma Metals, which was acquired in April 2007, or the pending acquisition of Welding Metallurgy.
The Company previously announced financial results guidance that includes a consolidation of AIM and Sigma Metals and Welding Metallurgy from their respective dates of acquisition. This guidance was for consolidated run rates by the end of 2007 for revenue within the range of $57 million to $60 million, earnings before interest, taxes, depreciation and amortization ("EBITDA") within the range of $4.5 million to $6.0 million, and net income within the range of $2.0 million to $2.5 million.
Air Industries Group considers EBITDA to be an important financial indicator of the Company's operational strength and performance, and uses this indicator when making decisions regarding investments in the various components of its business and acquisition valuations. Because EBITDA is not a measurement determined in accordance with generally accepted accounting principles ("GAAP"), and is thus susceptible to varying calculations, EBITDA, as presented, may not be directly comparable to other similarly titled measures reported by other companies.
ABOUT AIR INDUSTRIES GROUP, INC.
Air Industries Group, Inc. (OTCBB: GLDS) (formerly Gales Industries) is a holding company established to consolidate manufacturers, engineering integrators and specialized service providers to the aerospace/defense and commercial aviation industries. The Company is focused on flight safety and other critical componentry. Consolidation opportunities include companies operating within highly synergistic disciplines of manufacturing, technical services and strategic products distribution. The Company's strategy is to execute its consolidation principally amongst middle market aerospace/defense subcontractors. Air Industries Group offers a tailored exit strategy or management continuity strategy in exchange for qualified acquisitions, and targets technically superior organizations with revenues of up to $100 million annually. Information on the Company and its products may be found online at www.airindmc.com.
Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, firm backlog, projected backlog, potential future results and acquisitions, are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates, projections and forecasts made by management with respect to the Company's critical accounting policies, firm backlog, projected backlog, regulatory delays, government funding and budgets, matters pertaining to potential and pending acquisitions subject to and after closings, and other factors, including results of financial audits and general economic conditions, not within the Company's control. Certain of the Company's forward looking statements, with the projected backlog in particular, are formulated based on management's extensive industry experience and understanding and assessment of industry trends, customer requirements, and related government spending. Projected backlog may be subject to variability and may increase or decrease at any time based on a variety of factors, including but not limited to modifications of previously released orders, acceleration of orders under general purchase agreements, etc. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Source: Air Industries Group, Inc.
----------------------------------------------
Darrow Associates
Inc.
Jordan M. Darrow
631-367-1866
jdarrow@darrowir.com
ORGT - OrganiTech Announces $2 Million Investment; Resumes Trading on the OTC Bulletin Board
Jul 11, 2007 9:15:00 AM
YOKNEAM, ISRAEL -- (MARKETWIRE) -- 07/11/07 -- OrganiTech USA Inc. (OTCBB: ORGT) announced today that it entered into an agreement with 'Keren Katzir Debenture for Investment Ltd.' ("Katzir"), an Israeli investment company publicly traded on the Tel-Aviv Stock Exchange, for the investment of $2 million in the Company.
Pursuant to the Agreement, Katzir will invest $2 million in the Company in consideration for 10,000,000 shares of the Company's common stock (at a price per share of $0.20) constituting approximately 27.3% of the Company's issued and outstanding share capital (post-investment). Katzir will also be granted a 3 year warrant to purchase up to 3,846,154 shares of the Company's common stock for up to $1 million (exercise price of $0.26 per share).
The Company agreed as part of the investment to increase its board of directors to 11 members, 5 of whom will be nominated by Katzir. Mr. Yosi Hevron, one of Katzir's partners, is expected to be appointed by the board of directors as the Company chairman.
The transaction is expected to close by the end of next week.
On July 2, 2007, the shares of the Company's common stock resumed trading on the NASD's Over-The-Counter Bulletin Board ("OTCBB") under the symbol "ORGT" (OTCBB: ORGT). The transfer up from the Pink-Sheets (which resulted from the Company's past failure to comply with its reporting requirements) to the OTCBB formed part of the Company's rehabilitation program, under which it has filed all past required reports and is now in full compliance with its reporting requirements.
Mrs. Heli Ben-Nun, the Company's CEO, said: "We view Katzir as a strategic partner, and due to its management's expertise and proven capabilities, we have great confidence in its ability to contribute to the Company's future success. The new investment will allow us to extend our sales and marketing activities. With the expectation of increasing demand for hydroponics greenhouses in the coming years, we have confidence in our ability to realize these emerging opportunities. We also believe that resuming trading on the OTCBB will contribute to the tradability of the Company's shares."
Mr. Yosi Hevron, a partner in Katzir who is expected to be the chairman of the board of directors following consummation of the transaction, said: "We believe in the Company's product and its management. We believe that together we will increase the Company's value for its shareholders."
OrganiTech (OTCBB: ORGT) is a world leader in the supply of High-Tech hydroponics growing factories/greenhouses, enabling the growth of lettuce, green leafy vegetables, herbs and other plants, in a highly economic, automated, computerized controlled and clean environment. OrganiTech hydroponics solution, GrowTech2500, enables the production of extremely high yields, while maintaining low production costs and making optimal use of water, energy, labor and land. Our leading product, the GrowTech2500, backed with its patented and proprietary know-how is capable of producing over the course of a year 3-6 million lettuce heads -- about 20 times more than traditional outdoor soil-based cultivation methods and 5-7 times more than conventional greenhouse yields. With the long-distance transportation cost of lettuce and leafy vegetables becoming increasingly high due to increased cost of energy, our GrowTech2500 enables both local growers and importers of leafy vegetables to establish cost-effective local production hydroponics facilities near the point of sale, while competing with cheap local/imported products.
Founded in July 2006 by Mr. Rami Mandola, Katzir is a large private equity fund traded on the Tel Aviv Stock Exchange managing hundreds of millions of dollars in capital which are principally targeted for strategic investments in industries operated by Israel's Kibbutz movement. Katzir's management team has extensive industrial and financial experience and during 2006 invested approximately $16 million in four Israeli industrial companies operated by the Kibbutz movement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management, may be deemed to be forward-looking statements. The words "targets," "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions or negative variations thereof are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the investment disclosed in this press release, or the plans, intentions or expectations disclosed in our forward-looking statements and readers should not place undue reliance on the forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from the investment disclosed in this press release, or the other plans, intentions and expectations disclosed in the forward-looking statements made in this press release. Investors and others are therefore cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. We are subject to the risks and uncertainties described in our filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2006. You should read those factors as being applicable to all related forward-looking statements wherever they appear in this press release. We do not assume any obligation to update any forward-looking statements.
For Investment and Media inquiries, contact:
Yaron Shalem
+972-4-9937896
Have called, and suggest anyone interested to do the same...tic toc....!
HDVY - Health Discovery Corporation Settles Patent Infringement Suit against Ciphergen Biosystems, Inc.
Ciphergen to License HDC's Support Vector Machine Technology
Jul 6, 2007 9:27:00 AM
Copyright Business Wire 2007
SAVANNAH, Ga.--(BUSINESS WIRE)--
Health Discovery Corporation ("HDC") (OTCBB:HDVY) today announced that its patent infringement action against Ciphergen Biosystems, Inc. has been settled. Under the terms of the agreement, Ciphergen will pay $600,000 to HDC and receive a non-exclusive license to use HDC's support vector machines in applications for Ciphergen's proprietary SELDI-based technologies. Ciphergen also dropped all counter-claims against HDC.
"This settlement is an excellent resolution for our company and shareholders," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "It is also the second favorable outcome in both of the patent infringement suits we've filed, adding credence and momentum to our ongoing licensing efforts. HDC remains firmly committed to monetizing our valuable intellectual property through close collaboration and development with our business partners, but we will also continue to protect our patent portfolio through robust enforcement action when necessary."
Savannah-based Health Discovery Corporation (OTCBB:HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery sm. The Company's SVM and RFE-SVM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.
Source: Health Discovery Corporation
----------------------------------------------
Health Discovery Corporation
Daniel R. Furth
813-716-4783
investor@healthdiscoverycorp.com
www.healthdiscoverycorp.com
CLSC - Cobalis Reports Phase III Trial Results for PreHistin(TM) in Seasonal Allergic Rhinitis
Low Symptom Levels in Overall Patient Population Lead to Inconclusive Outcome
Jul 6, 2007 9:15:00 AM
Copyright Business Wire 2007
IRVINE, Calif.--(BUSINESS WIRE)--
Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported preliminary top-line results from two Phase III clinical trials for its drug PreHistin(TM) in patients with moderate to moderately severe seasonal allergic rhinitis, commonly known as hay fever. The trials showed very low symptom levels in both placebo and PreHistin-treated patient groups, thereby leaving no room to demonstrate a meaningful drug effect.
In the randomized, six week, placebo-controlled trials involving a total of 1,551 subjects, PreHistin did not achieve statistically significant differences from placebo in the primary measure of efficacy, the reduction in total nasal symptom score (TNSS). However, the TNSS data for placebo-treated patients was far lower than would be expected for the moderate to moderately severe patient population called for in the protocol. Low pollen counts in many of the regions during the time PreHistin was being tested may have resulted in low mean placebo symptom scores for the overall study population.
The trials showed that PreHistin was well tolerated and thus contributed positively to the safety record of PreHistin's active ingredient, cyanocobalamin.
A comparison of pre- and post-treatment blood levels of cobalamin demonstrated for the first time in a large study population that delivery of cyanocobalamin via sublingual lozenges resulted in significant increases in cobalamin blood levels.
Cobalis' Chief Scientific Officer Ernest Armstrong commented: "Showing a meaningful reduction in allergy symptoms when the symptoms never increased throughout the pollen season to the desired moderate to moderately severe level is next to impossible. It's like trying to prove that a pump can pump water out of a swimming pool when there is almost no water in the pool to begin with. Other pharmaceutical companies studying allergy drugs have reported problems with their clinical trials because of low symptom scores in an allergy season, with at least one report in an analogous situation occurring in the 2006 ragweed season when we conducted our trials."
The Company's chief executive officer, Gerald Yakatan, Ph.D., said, "It is unfortunate that nature did not provide the level of allergy symptoms we needed for our studies, but we continue to believe in PreHistin as a product. Cobalis remains committed to a corporate strategy based on bringing PreHistin to the consumer market. Going forward, we will continue pursuing FDA approval of PreHistin as an OTC drug if we assess the prospects for such approval to be favorable, but we will also investigate other potential marketing channels."
Details of the Study
The parallel, randomized, double-blind Phase III clinical trials for PreHistin involved 1,551 patients at 23 sites across the central, southern and eastern U.S. The patients received either a placebo or a 3.3-mg sublingual dosage of PreHistin twice daily for three weeks prior to the onset of the ragweed allergy season and for an additional three weeks into the allergy season. The primary efficacy parameter for each trial was the difference in the mean reduction in Total Nasal Symptom Score (TNSS) observed between the placebo and PreHistin over the fourth, fifth and sixth weeks of the studies. TNSS is a 12-point scale derived by summing and averaging all a.m. and p.m. scores for four symptoms: sneezing, runny nose, nasal congestion and nasal itch. Each symptom is given a score - 0 (none), 1 (mild), 2 (moderate) or 3 (severe) - resulting in a maximum recorded daily mean TNSS of 12. Patients maintained electronic diaries twice daily, self-rating their average symptoms over the previous 12 hours.
The Company delayed reporting preliminary top-line analyses from the two Phase III trials due to diary data entry inconsistencies. To evaluate whether these inconsistencies were sufficient to represent a systematic error that could affect the outcome of the analyses, the Company engaged an expert external consultant to conduct an audit of the electronic diary database. The study audit found that the electronic diary system functioned correctly and the diary data entered by the patients were correct. The inconsistencies noted earlier were primarily human errors that were corrected and did not alter the study outcomes.
About Seasonal Allergic Rhinitis
Seasonal allergic rhinitis, otherwise known as hay fever, is an allergic reaction to airborne substances such as pollen that get into the upper respiratory passages and cause the body to produce antibodies and release histamine. Histamine makes the upper respiratory membranes swell and produce typical allergy symptoms such as sneezing, runny nose and nasal congestion. In the U.S., approximately 50 million people suffer from seasonal allergic rhinitis, with related healthcare costs exceeding $7 billion annually. Ragweed is the single most common seasonal allergen, affecting up to 75% of those with seasonal allergic rhinitis, or 30 million Americans. Current treatment options are mainly limited to symptomatic therapies to provide temporary relief and conventional allergy immunotherapy by injection.
About PreHistin
PreHistin is a sublingual lozenge that delivers its active ingredient through the buccal membrane directly into the bloodstream. The active ingredient, cyanocobalamin, has a well-known safety profile and has been shown in studies to relieve symptoms related to seasonal allergies, asthma and other atopic allergic diseases. PreHistin may represent a novel approach to treatment by rectifying imbalances in the immune system that trigger the over-production of allergy symptom-causing substances including histamines. By preventing or reducing the over-production of these substances before they are released from cells, the need to block the symptom-causing effects of histamine may be eliminated, or minimized. PreHistin is patented for the treatment of atopic allergic diseases such as seasonal and perennial allergies, dermatitis, migraine, food allergies and asthma.
About Cobalis Corp.
Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy medication in Phase III clinical development. For further information, visit www.cobalis.com
Safe Harbor Statement: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to securing funding for ongoing operations including clinical trials, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the development of competing products by our competitors; uncertainties related to the Company's dependence on third parties and partners; and those risks described in our SEC filings and annual report on Form 10-KSB filed with the SEC on July 14, 2006.
Source: Cobalis Corp.
----------------------------------------------
Investor Relations International
Haris Tajyar
818-382-9702
htajyar@irintl.com
CLSC - Cobalis Reports Phase III Trial Results for PreHistin(TM) in Seasonal Allergic Rhinitis
Low Symptom Levels in Overall Patient Population Lead to Inconclusive Outcome
Jul 6, 2007 9:15:00 AM
Copyright Business Wire 2007
IRVINE, Calif.--(BUSINESS WIRE)--
Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported preliminary top-line results from two Phase III clinical trials for its drug PreHistin(TM) in patients with moderate to moderately severe seasonal allergic rhinitis, commonly known as hay fever. The trials showed very low symptom levels in both placebo and PreHistin-treated patient groups, thereby leaving no room to demonstrate a meaningful drug effect.
In the randomized, six week, placebo-controlled trials involving a total of 1,551 subjects, PreHistin did not achieve statistically significant differences from placebo in the primary measure of efficacy, the reduction in total nasal symptom score (TNSS). However, the TNSS data for placebo-treated patients was far lower than would be expected for the moderate to moderately severe patient population called for in the protocol. Low pollen counts in many of the regions during the time PreHistin was being tested may have resulted in low mean placebo symptom scores for the overall study population.
The trials showed that PreHistin was well tolerated and thus contributed positively to the safety record of PreHistin's active ingredient, cyanocobalamin.
A comparison of pre- and post-treatment blood levels of cobalamin demonstrated for the first time in a large study population that delivery of cyanocobalamin via sublingual lozenges resulted in significant increases in cobalamin blood levels.
Cobalis' Chief Scientific Officer Ernest Armstrong commented: "Showing a meaningful reduction in allergy symptoms when the symptoms never increased throughout the pollen season to the desired moderate to moderately severe level is next to impossible. It's like trying to prove that a pump can pump water out of a swimming pool when there is almost no water in the pool to begin with. Other pharmaceutical companies studying allergy drugs have reported problems with their clinical trials because of low symptom scores in an allergy season, with at least one report in an analogous situation occurring in the 2006 ragweed season when we conducted our trials."
The Company's chief executive officer, Gerald Yakatan, Ph.D., said, "It is unfortunate that nature did not provide the level of allergy symptoms we needed for our studies, but we continue to believe in PreHistin as a product. Cobalis remains committed to a corporate strategy based on bringing PreHistin to the consumer market. Going forward, we will continue pursuing FDA approval of PreHistin as an OTC drug if we assess the prospects for such approval to be favorable, but we will also investigate other potential marketing channels."
Details of the Study
The parallel, randomized, double-blind Phase III clinical trials for PreHistin involved 1,551 patients at 23 sites across the central, southern and eastern U.S. The patients received either a placebo or a 3.3-mg sublingual dosage of PreHistin twice daily for three weeks prior to the onset of the ragweed allergy season and for an additional three weeks into the allergy season. The primary efficacy parameter for each trial was the difference in the mean reduction in Total Nasal Symptom Score (TNSS) observed between the placebo and PreHistin over the fourth, fifth and sixth weeks of the studies. TNSS is a 12-point scale derived by summing and averaging all a.m. and p.m. scores for four symptoms: sneezing, runny nose, nasal congestion and nasal itch. Each symptom is given a score - 0 (none), 1 (mild), 2 (moderate) or 3 (severe) - resulting in a maximum recorded daily mean TNSS of 12. Patients maintained electronic diaries twice daily, self-rating their average symptoms over the previous 12 hours.
The Company delayed reporting preliminary top-line analyses from the two Phase III trials due to diary data entry inconsistencies. To evaluate whether these inconsistencies were sufficient to represent a systematic error that could affect the outcome of the analyses, the Company engaged an expert external consultant to conduct an audit of the electronic diary database. The study audit found that the electronic diary system functioned correctly and the diary data entered by the patients were correct. The inconsistencies noted earlier were primarily human errors that were corrected and did not alter the study outcomes.
About Seasonal Allergic Rhinitis
Seasonal allergic rhinitis, otherwise known as hay fever, is an allergic reaction to airborne substances such as pollen that get into the upper respiratory passages and cause the body to produce antibodies and release histamine. Histamine makes the upper respiratory membranes swell and produce typical allergy symptoms such as sneezing, runny nose and nasal congestion. In the U.S., approximately 50 million people suffer from seasonal allergic rhinitis, with related healthcare costs exceeding $7 billion annually. Ragweed is the single most common seasonal allergen, affecting up to 75% of those with seasonal allergic rhinitis, or 30 million Americans. Current treatment options are mainly limited to symptomatic therapies to provide temporary relief and conventional allergy immunotherapy by injection.
About PreHistin
PreHistin is a sublingual lozenge that delivers its active ingredient through the buccal membrane directly into the bloodstream. The active ingredient, cyanocobalamin, has a well-known safety profile and has been shown in studies to relieve symptoms related to seasonal allergies, asthma and other atopic allergic diseases. PreHistin may represent a novel approach to treatment by rectifying imbalances in the immune system that trigger the over-production of allergy symptom-causing substances including histamines. By preventing or reducing the over-production of these substances before they are released from cells, the need to block the symptom-causing effects of histamine may be eliminated, or minimized. PreHistin is patented for the treatment of atopic allergic diseases such as seasonal and perennial allergies, dermatitis, migraine, food allergies and asthma.
About Cobalis Corp.
Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy medication in Phase III clinical development. For further information, visit www.cobalis.com
Safe Harbor Statement: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to securing funding for ongoing operations including clinical trials, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the development of competing products by our competitors; uncertainties related to the Company's dependence on third parties and partners; and those risks described in our SEC filings and annual report on Form 10-KSB filed with the SEC on July 14, 2006.
Source: Cobalis Corp.
----------------------------------------------
Investor Relations International
Haris Tajyar
818-382-9702
htajyar@irintl.com
RXPC - Rx Processing Corp. Cancels July Stock Dividend 2007
(this is an example of pinkies that are shorted pre divvy imo)
Jul 6, 2007 8:57:00 AM
2007 PrimeNewswire, Inc.
WILMINGTON, Del., July 6, 2007 (PRIME NEWSWIRE) -- Rx Processing Corporation (Pink Sheets:RXPC), a source of low-cost prescription medications and diagnostic laboratory tests for millions of Americans, announces the board of directors cancels the July stock dividend announced June 19th 2007.
Rx Processing Corp., with the board of directors, today moved to cancel the July stock dividend as to continue the evaluation on the severity of our operational issues in furtherance of the overall mission.
Chairman Peter Fiorillo stated, "I have been left with no choice but to cancel this stock dividend to further my (our) mission to service the under and uninsured due to financial and technology issues along with the complete erosion of our share price."
Rx Processing Corp., an innovator in the distribution of pharmaceutical medications and laboratory diagnostics managed through storefront locations, is deploying a direct to consumer delivery business model that fulfills the needs of under and uninsured clients' health care needs. The company provides access to FDA approved brand-name and generic medications, thousands of laboratory diagnostics with access to 4,000+ CLIA-certified patient service centers for specimen collection. Rx Processing Corp. estimates that more than 48 million United States citizens would benefit from these company programs.
Safe Harbor Statement:
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including those about the company's future expectations, revenues and earnings, and all other forward-looking statements (i.e. operational results and sales) are subject to assumptions and beliefs based on current information known to the company and factors that are subject to uncertainties, risk and other influences, which are outside the company's control, and may yield results differing materially from those anticipated.
CONTACT: Rx Processing Corporation
Peter Fiorillo
(866) 616-9724
http://www.rxprocessingcorp.com
CLXS - Collexis Holdings, Inc. Announces OTC Listing
Jul 3, 2007 8:49:00 AM
Common Stock to be Traded Under CLXS Symbol
COLUMBIA, SC, July 3 /CNW/ - Leading developer of search and knowledge discovery software, Collexis Holdings, Inc. announced today that Collexis's shares of common stock are eligible for trading on the OTC Bulletin Board (OTC Bulletin Board: CLXS). Its ticker symbol is CLXS.
Bill Kirkland, CEO Collexis Holdings Inc., said, "As we continue to expand our global operations, this listing signals the beginning of a new era of growth for Collexis, coupled with new opportunities for investors to grow with us. We believe this offering will enhance our visibility and provide greater access to institutional and retail investors while we focus on profitably growing our business."
Co-founder and Collexis B.V. CEO., Peter Van Praag, stated, "It is truly exciting for me to see the company I founded seven years ago now has a worldwide presence and has become a publicly traded company. As the US operation is in full swing, we are looking forward to the future growth of Collexis."
Collexis Holdings, Inc.
Collexis Holdings, Inc., a global knowledge discovery company since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis patented technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content to create applications. The results are often described as 'finding needles in many haystacks'. Through this novel approach, Collexis can build unique applications to search, index, and aggregate information as well as prioritize, trend and predict data based on sources in multiple fields, without the limitations of language or dialect. The company's mission is to develop software supporting knowledge retrieval and discovery across multiple industries. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC Bulletin Board: CLXS). For more information visit www.collexis.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
----------------------------------------------
Media: Darrell W. Gunter of Collexis Holdings
Inc.
(803) 727-1113
gunter@Collexis.com
Web Site: http://www.collexis.com/
SSGY - South Sea Energy Announces New Trading Symbol
Jul 2, 2007 9:00:00 AM
HOUSTON, TX -- (MARKETWIRE) -- 07/02/07 -- South Sea Energy Corp. (OTCBB: SSGY), formerly Henley Ventures, Inc. (OTCBB: HNVN) ("South Sea" or the "Company"), wishes to announce that at opening of trading on July 2nd, 2007, the Company will trade on the NASD's Over-the-Counter Bulletin Board ("OTCBB") under the symbol SSGY.
Details regarding the symbol change will be submitted to the Securities and Exchange Commission ("SEC") as part of the Company's Form 8-K filing dated July 2, 2007.
About South Sea Energy Corp. (Formerly Henley Ventures, Inc.) (OTCBB: SSGY)
South Sea Energy Corp. ("South Sea") is an emerging junior energy company specializing in the exploration and development of coal bed methane in Indonesia's vast coal reserves. The Company is led by industry-leading coal bed methane experts that have extensive experience in developing junior oil and gas companies and have identified significant opportunities that position the Company as a potential front-runner in the country's burgeoning unconventional gas sector.
Forward-Looking Statements
Except for statements of historical fact, the information presented herein may contain forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which South Sea Energy Corp., Henley Ventures, Inc., or any affiliates, has little or no control.
On Behalf of the Board
South Sea Energy Corp.
-------------------------
Alan T. Charuk, President
Investor Relations Contact:
Great Northwest Investor Relations, Inc.
1-888-697-4712
Y/W, very much looking forward 2 the future of this company also. should not b long now imo.
BQTG ...nice news,
June 28, 2007 - 6:30 AM EDT
BioQuest Technologies Board of Directors to Retire 250 Million Shares of Common Stock
Retired Stock Would Dramatically Reduce the Number of Outstanding Shares and Increase Shareholder Value
and yesterday
Sherwin-Williams and BioQuest Technologies to Create a Private Label Antimicrobial Paint for the Lynd Company
RLLC - Real Logic, Inc. Announces Trading
Jun 27, 2007 1:47:00 PM
PALM BEACH, Fla., June 27 /PRNewswire-FirstCall/ -- Real Logic Inc. (OTC: Bulletin Board: RLLC) issued a statement today. "We announce that Real Logic, Inc. has been cleared for trading of its quoted stock on June 22, 2007," states Brad Tolley, CEO of Real Logic, Inc.
About Real Logic
Real Logic, Inc., through subsidiaries, is developing alternative transportation vehicles for resort, neighborhood, utility, and recreational uses worldwide. Depending on how they are outfitted, the vehicles may be used for neighborhood transportation; four-wheel-drive, off-road safari; resort; security patrol; construction; and farm utility purposes. For more information, please visit http://www.reallogic.net.
Forward - Looking Statements
This news release may contain forward-looking statements under the provisions of the Private Securities Litigation Act of 1995, as amended, that are subject to inherent risks or uncertainties. These risks and uncertainties are described from time to time in the annual, quarterly and other periodic reports filed by the company with the Securities and Exchange Commission. For additional information about risks and uncertainties and a discussion of Real Logic's financial statements and footnotes, see documents filed by Real Logic with the SEC, and all periodic filings made with the SEC. Real Logic assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
Brad Tolley
Real Logic, Inc.
340 Royal Poinciana Way Suite 326B
Palm Beach, FL 33480
561-833-9808 Phone
561-655-5548 Fax
http://www.reallogic.net
info@reallogic.net
SOURCE Real Logic Inc.
----------------------------------------------
Brad Tolley of Real Logic Inc.
phone
+1-561-833-9808
fax
+1-561-655-5548
info@reallogic.net
re: GKSY
PR out and on the bottom
Investor Relations
1-866-THE-APPL(E)
I will pass.
Uh yeah...just kidding, recently posted just about the same opinion as your.
SBSH working hard, 300 shares Take the price down to get shares.
bidwacker...!
GVHL (shell up 26900% lol) - Global Vision Majority Shareholder Announces That It Has Signed An Agreement To Sell The Controlling Interest
SAN DIEGO, CA, Jan. 29 /PRNewswire/ - Global Vision Holdings, Inc. (Pink Sheets: GVHL), a Nevada company, announced today that its CEO, Mr. Jack Chang, the majority shareholder, is in the process of transferring the majority of his equity position of GVHL to an undisclosed purchaser. This deal has been in the works for months and the two sides have reached a decision on various operational matters. Mr. Chang will maintain minority equity in the surviving company and will be actively involved in the business and marketing strategies and activities of ATM Business.
World Market
Global Vision's CEO, Jack Chang, who is the co-inventor of the ATM, said, 'The purchaser is well financed, has demonstrated revenue and is in a strong position to expand its market share internationally. International market expansion is where I can lend a tremendous help since I have been working on the international front for the last two and half years. We see this as a win-win position for all concerned and especially our shareholders who have been anticipating this transaction for a very long time.'
About Global Vision Holdings
Global Vision Holdings, Inc. (Pink Sheets: GVHL), the business developer and wholesale marketer (with agents worldwide), offers advanced payment systems products & services (for banked as well as un-banked people) that include:
- Prepaid Debit Cards - For end users, groups & co-branding issuers
- Credit & debit card processing outsourcing - for financial
institutions
- Design, program management & outsourcing of 'Transaction Acquiring
Networks' for banking, as well as retail (bill payments & prepaid
top-ups), transaction switching & processing.
Global Vision's revenue model strives to create both initial and recurring revenue streams from a global customer base through mass distribution marketing channels.
Mr. Chang is also a pioneer in the use of magnetic strips on bank cards, electronic funds transfer systems and PC-based in-bank systems.
He has been CEO of payment services corporations and business and marketing strategist for Global 500 banks & corporations.
Mr. Chang is the co-inventor of the ATM machine. For details, please see: http://www.Global-Vision.com/Bio.asp .
Legal Notice Regarding Forward-Looking Statements: 'Forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. Global Vision disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to, risks associated with changes in general economic and business conditions.
SOURCE Global Vision Holdings, Inc.
Source: PR Newswire (January 29, 2007 - 2:35 PM EST)
News by QuoteMedia
www.quotemedia.com
MDSC - Infotonics/Mediscience Announce Funding and Development Agreement
Jun 26, 2007 12:02:00 PM
Copyright Business Wire 2007
CHERRY HILL, N.J.--(BUSINESS WIRE)--
Mediscience Technology Corp. (MTC) (OTC:MDSC) ("Mediscience"), executed an agreement dated June 21, 2007 with equity partner Infotonics Technology Center Inc.,(ITC) a Rochester New York not-for-profit corporation, under which ITC agrees to develop through advances in optical, mechanical, electrical, software and diagnostic aspects, and to commercialize, Mediscience's medical diagnostic systems via two initial advanced medical products, the Optical Biopsy Pill (OBP) and the CD Ratiometer (CDR) using tissue auto-fluorescence to detect disease states. The companies have agreed to a series of milestones to be achieved through October 2007 for which Mediscience has agreed to pay $2,000,000. ITC will continue to use its best efforts to secure grant awards to meet the $2,000,000 obligation of Mediscience. The Agreement is also intended to benefit BioScopix, Inc., Mediscience's wholly-owned subsidiary that is expected to own the medical diagnostic systems using tissue auto-fluorescence to detect disease states as that technology is further developed. The parties expect impact funding from a NYSTAR grant award of $750,000 applied for by Infotonics and the receipt by subsidiary "BioScopix" of an initial $2-3M of bridge funding through Empire Financial Group Inc NY, to continue commercialization.
The terms of the Agreement described above are only a summary of the Agreement qualified in their entirety by reference to the Agreement filed as Exhibit 10.1 in SEC Form 8-K. dated June 25, 2007.
(MTC/BioScopix Inc.) CEO Peter Katevatis Esq. says, "The relationship with equity partner Infotonics is synergistic and strategic, leveraging Infotonics Nano-Technology and Micro-System capabilities and broad resources to provide MTC with an exceptional state of the art advantage, over competitors. (see below Syracuse May 24, 2006 and CityGroup Oct -1-2004 Reports). This agreement properly places MTC proprietary non-invasive imaging technology for molecular detection of cancer and physiological change in the commercialization stage/track. With Infotonics assistance we intend, to use the net proceeds of the Empire Financial Group NY $2 to 3 Million Bridge funding and prospective $5 to $10M Firm commitment Initial Public Offering to fund commercialization of our Optical Biopsy Pill (OBP) and the CD Ratiometer (CDR)."
EMPIRE FINANCIAL GROUP
Empire Financial is a NASD registered broker dealer approved to provide a broad range of securities services to investors and institutions in all 50 states. The company's home office is located in Longwood, FL.
INFOTONICS TECHNOLOGY CENTER INC.
Infotonics is a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation, a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems.
(NYSTAR) NY OFFICE OF SCIENCE, TECHNOLOGY AND ACADEMIC RESEARCHKey goals are: Spur economic development in New York State through academic research; Coordinate and organize New York's wide array of science and technology informational resources and provide our academic, business, and research communities access to these resources.
ABOUT MEDISCIENCE TECHNOLOGY CORP.
Mediscience Technology Corporation and subsidiary are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Their exclusive protected non-invasive technology combines advantages of real-time results with enhanced diagnostic sensitivity and specificity as compared with other methods of cancer detection.
INVESTOR NOTICE
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks and uncertainties including market conditions and FDA filings and/or approvals, required before the Camera Pill or the CD Ratiometer can be sold or licensed for use in the United States. This press release is intended to comply with Rule 135c promulgated under the Securities Act of 1933. Submitted in full compliance with sections 8-K 1.01 and 2.01 re: "materiality" as applicable and in fulfillment of SEC Section 6, 6.01 Regulation (FD) Full Disclosure, and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
REFERENCE
8-K filing dated June 25, 2007
8-K filing Syracuse Univ. May 24, 2006 72 Pg Report
CityGroup/Smith Barney Report 10-1-2004 by Peter Bye. Page 20
www.Infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp
www.cunyphotonics.com
MEDISCIENCETECH.com
Source: Mediscience Technology Corp.
----------------------------------------------
Mediscience/BioScopix Inc.
Peter Katevatis
Esq.
Chairman CEO
metpk@aol.com
or
Infotonics Tech Ctr.
David Smith
Pres. CEO
585-919-3001
David.R.Smith@infotonics.org
EXPH - Expo Holdings, Inc. Signs Two-Year Agreement With Novalis, Inc., North America's Leading Vinyl Tile Manufacturer
Jun 26, 2007 9:53:00 AM
NORTH WILKESBORO, NC -- (MARKETWIRE) -- 06/26/07 -- Expo Holdings, Inc. (PINKSHEETS: EXPH) announces that via its solely owned subsidiary D&D Displays, Inc. it has signed a two-year agreement to supply in-store displays, and point of purchase related items to Novalis, Inc.
J.D. Brown, Chairman and CEO of Expo Holdings, Inc., stated, "We have supplied Novalis, Inc. several million dollars worth of POP and retail fixtures over the past 5 years (through D&D Displays, Inc.). We are very pleased to have been chosen again as their primary display and point of purchase supplier for the next two years. Novalis, Inc. is the kind of customer all display companies desire, they are honorable, knowledgeable, and they pay their bills on time or early in almost every case. We have the potential to complete over 2 million in sales to Novalis Inc. over the next two years. These sales will be primarily related to their growth with a Fortune 100 retailer. Novalis, Inc. operates the website www.novalis-intl.com."
D&D Displays, Inc. is a wholly owned subsidiary of Expo Holdings, which specializes in custom cabinetry and high end store fixtures for retail vendors such as Lowe's, Newell-Rubbermaid, Inc., Bosch Tool Corporation, Kronotex, USA, and S&K Men's Wear. D&D Displays has been in operation since 2000 and joined Expo Holdings in 2006.
Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such proclamations about the Company's future expectations, including future revenues and earnings, technology effectiveness and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Contact:
Expo Holdings, Inc.
J.D. Brown
CEO
336-667-8765
jdbrown@dddisplays.com
116 Shaver Street
North Wilkesboro, NC
CSSK - Cruisestock, Inc. Shareholders Approve 7 for 1 Forward Stock Split Among Other Items At Special Shareholders Meeting
Also, Change Of Company Name And State Domicile Along With Election of Board Of Directors And Approval of the Company's 2007 Incentive Stock Option Plan
Jun 26, 2007 9:15:00 AM
Copyright Business Wire 2007
TAMPA, Fla.--(BUSINESS WIRE)--
Cruisestock, Inc. ("CSSK" or the "Company") (OTCBB:CSSK) through its Chairman/CEO, Michael Nole, today announced the results of a Special Shareholders meeting held June 21, 2007 in Tampa Florida. The following actions were all adopted and approved:
1. Proposal to elect the following two nominees as Directors: Michael Nole and Bryan McGuire.
2. Proposal to approve the "Redomestication" of the Company into Florida, which will be accomplished by merging (the "Merger") the Company into its newly-formed, wholly-owned Florida subsidiary named Brookside Technologies Holding Corp., with the Florida subsidiary corporation being the survivor in the Merger (the "Surviving Company").
3. Proposal to approve a forward split of the Company's shares of common stock concurrently with the effectiveness of the Redomestication on a ratio of 7 for 1.
4. Proposal to approve the articles of incorporation for the Surviving Company.
5. Proposal to approve the Company's 2007 Incentive Stock Option Plan, which was approved by the Company's board of directors on April 19, 2007.
It is currently anticipated that the Redomestication and forward stock split will become effective at the opening of the market on July 6, 2007. Upon the effectiveness of the Merger, the Company's name will become Brookside Technologies Holding Corp. and the Company will receive a new stock ticker symbol.
Mike Nole Chariman/CEO stated: "I am happy to report that all the above items, many of which were just 'final steps' in bringing Brookside public, have now been approved and will shortly be completed." Nole went on to say: "Things are moving along smoothly and rapidly on the acquisition of US Voice and Data ("USVD") which was noticed as a Letter of Intent in our recent SEC 8K filing. We still can make no assurances that the acquisition will be successfully consummated. However, I anticipate to be able to update the shareholders on this event shortly."
About Cruisestock, Inc.
Cruisestock, Inc., whose name will be changed shortly to Brookside Technologies Holding Corp., is a holding company whose goal is to consolidate through mergers, acquisitions and asset purchases of like companies looking to capitalize on the highly specialized market of providing turnkey converged voice and data solutions for companies of all sizes and types.
Current Subsidiary
Brookside Technology Partners (TEXAS)
Brookside Technology Partners, Inc. ("Brookside"), headquartered in Austin, Texas, is a provider and global managed service company specializing in selling, designing, analyzing and implementing converged Voice over IP (VoIP), data and wireless business communications systems and solutions for commercial and state/government organizations of all types and sizes. Brookside is a leading VoIP reseller and professional services vendor with over 300 BCM installations that have various forms of networked or VoIP functionality. More information on Brookside can be found at the Brookside website at http://www.brooksideus.com.
Forward-Looking Statement: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the uncertainties related to the USVD acquisition, the effect of changing economic conditions, customer acceptance of products and other risks and uncertainties, including those risks set forth in Cruisestock's Form 8-K filed on February 27, 2007 with the SEC. Such forward-looking statements are not guarantees of performance, and Cruisestock and Brookside results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Cruisestock and Brookside undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Source: Cruisestock, Inc.
----------------------------------------------
Cruisestock
Inc.
Tampa
Michael Nole
CEO
813-342-0337
or
Bryan McGuire
CFO
813-865-6333
TMMI - TMM Inc. Announces Suspected Illegal Shares and Unauthorized Expansion of TMM Stock
Jun 25, 2007 12:55:00 PM
BEVERLY HILLS, CALIFORNIA -- (MARKETWIRE) -- 06/25/07 -- TMM INC. (PINK SHEETS: TMMI) President Michael Fernandez announced today that he suspects that unauthorized shares of TMM stock have been issued and entered the public market illegally.
Fernandez announced that Corene Dion King, a director of TMM, has without authorization from the board of directors or approval of a majority of the common shareholders filed an amendment to articles of incorporation of the company increasing the authorized shares of common stock from 100 million shares to 750 million shares and issued 169 million additional shares of common stock.
Fernandez also stated that he has notified the Securities and Exchange Commission and the Nevada Secretary of State office and requested an investigation. Fernandez further stated that these issuances have not been approved by the legitimate board directors of TMM Inc. and that he has retained legal counsel to investigate this suspected illegal stock issuance and to take immediate legal action to have the transactions cancelled.
Michael Fernandez, President
Contacts:
TMM Inc.
Michael Fernandez
President
(323) 556-0819
Email: info@tmmi.us
Website: www.tmmi.us